Cytomegalovirus DNAemia and treatment following allogeneic stem cell transplantation with a focus on long-term outcome

References

• Meyers JD, Spencer HC, Watts JC, Gregg MB, Stewart JA, Troupin RH, . Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med 1975;82:181–8.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol 2000;16:25–40.
   PubMed Web of Science ®Google Scholar
• Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, . Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995;86:2815–20.
   PubMed Web of Science ®Google Scholar
• Ljungman P. Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant 1998; 21(Suppl 2):S72–4.
   Google Scholar
• Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478–88.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, . Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004;33:1075–81.
   PubMedGoogle Scholar
• Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lönnqvist B, . Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998;66: 1330–4.
   PubMed Web of Science ®Google Scholar
• Crippa F, Corey L, Chuang EL, Sale G, Boeckh M. Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Infect Dis 2001;32:214–9.
   PubMed Web of Science ®Google Scholar
• Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173–8.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295–304.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094–7.
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, . Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99: 1159–64.
   PubMed Web of Science ®Google Scholar
• Studahl M, Ricksten A, Sandberg T, Elowson S, Herner S, Sall C, . Cytomegalovirus infection of the CNS in non-compromised patients. Acta Neurol Scand 1994;89: 451–7.
   PubMed Web of Science ®Google Scholar
• Yun Z, Lewensohn-Fuchs I, Ljungman P, Ringholm L, Jonsson J, Albert J. A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients. J Virol Methods 2003;110:73–9.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, . Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006;91:78–83.
   PubMed Web of Science ®Google Scholar
• Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, . A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598–603.
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, . Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 2008;87:310–8.
   PubMed Web of Science ®Google Scholar
• Boström L, Ringdèn O, Jacobsen N, Zwaan F, Nilsson B. A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors—acute graft-versus-host disease, and splenectomy. Transplantation 1990;49:1100–5.
   PubMedGoogle Scholar
• Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, . Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407–14.
   PubMed Web of Science ®Google Scholar
• Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, . Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000;25: 757–63.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H, . Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388–92.
   PubMed Web of Science ®Google Scholar